Edition:
United Kingdom

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

36.14USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$36.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
245,262
52-wk High
$53.70
52-wk Low
$19.23

Latest Key Developments (Source: Significant Developments)

Novocure And Zai Lab Announce Strategic Collaboration
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Zai Lab Ltd ::NOVOCURE AND ZAI LAB ANNOUNCE STRATEGIC COLLABORATION WITH A LICENSE AGREEMENT FOR TUMOR TREATING FIELDS IN GREATER CHINA.ZAI LAB LTD - ZAI LAB WILL SUPPORT ENROLLMENT OF CHINESE PATIENTS TO CERTAIN CLINICAL TRIALS INVESTIGATING TUMOR TREATING FIELDS.ZAI LAB LTD - NOVOCURE WILL RECEIVE A $15 MILLION UPFRONT PAYMENT.ZAI LAB LTD - NOVOCURE IS ALSO ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS UPON ACHIEVEMENT OF CERTAIN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ZAI LAB LTD - NOVOCURE GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO COMMERCIALIZE TUMOR TREATING FIELDS IN CHINA, HONG KONG, MACAU AND TAIWAN.ZAI LAB LTD - ZAI LAB WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS IN GREATER CHINA.  Full Article

Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
Friday, 20 Apr 2018 

April 20 (Reuters) - Novocure Ltd ::NOVOCURE LTD SAYS EXECUTIVE CHAIRMAN WILLIAM DOYLE'S FY 2017 TOTAL COMPENSATION WAS $23.8 MILLION - SEC FILING.  Full Article

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER.NOVOCURE LTD - RECEIVED A U.S. FOOD AND DRUG ADMINISTRATION INVESTIGATIONAL DEVICE EXEMPTION APPROVAL TO INITIATE ITS PANOVA 3 CLINICAL TRIAL.  Full Article

Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA.NOVOCURE-‍JAPANESE MINISTRY OF HEALTH, LABOUR & WELFARE APPROVED RECOMMENDATION TO PROVIDE REIMBURSEMENT FOR OPTUNE TO TREAT NEWLY DIAGNOSED GLIOBLASTOMA​.  Full Article

Novocure reports qtrly ‍loss per share $0.13​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Novocure Ltd :Novocure Ltd - Qtrly ‍loss per share $0.13​.Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​.  Full Article